GLP-1 for PCOS: How This Treatment Works

GLP-1 receptor agonists treat PCOS by targeting insulin resistance, one of the central drivers of the syndrome. These drugs, originally developed for type 2 diabetes and obesity, lower insulin levels and promote weight loss, which in turn reduces the excess androgens responsible for many PCOS symptoms. The result is a cascade of improvements: lower testosterone, more regular periods, better metabolic markers, and in some cases, restored fertility. But how this all connects, and what the research actually shows about each of these outcomes, is worth understanding in detail.

Why Insulin Matters So Much in PCOS

PCOS is often described as a hormonal disorder, and it is, but the hormonal chaos frequently starts with insulin. Most women with PCOS have some degree of insulin resistance, partly from genetic predisposition and partly amplified by excess weight.¹ When your body becomes resistant to insulin, it compensates by pumping out more of it. That extra circulating insulin does something particularly harmful in PCOS: it stimulates the ovaries to produce more androgens like testosterone. High androgens then drive the symptoms people associate with the condition, including irregular cycles, acne, excess hair growth, and difficulty ovulating.

This means that anything capable of reducing insulin levels has the potential to improve PCOS across the board, not just metabolically but reproductively and cosmetically. That is exactly where GLP-1 drugs enter the picture.

How GLP-1 Drugs Work

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It signals your pancreas to produce insulin in a glucose-dependent way, meaning it only boosts insulin secretion when blood sugar is actually elevated. GLP-1 receptor agonists are synthetic versions of this hormone, designed to last much longer in the body than the natural form. Their effects include stimulating insulin release when needed, slowing gastric emptying so food moves through you more gradually, and reducing appetite by acting on brain regions involved in hunger and satiety.²

For PCOS specifically, these effects converge in a useful way. By improving how the body handles glucose and insulin, GLP-1 drugs reduce the hyperinsulinemia that drives excess androgen production. Simultaneously, by suppressing appetite and slowing digestion, they produce meaningful weight loss, which further improves insulin sensitivity. The drugs also appear to reduce what some researchers call “food noise,” the persistent mental preoccupation with eating that makes weight management so difficult.

There is also an interesting angle involving the body’s own GLP-1 production. Research has found that women with obesity and PCOS, particularly those who have progressed to prediabetes, show an impaired GLP-1 response compared to women without the syndrome.³ This suggests that PCOS may involve a built-in deficit in this hormonal signaling pathway, which makes the case for supplementing it with a medication somewhat intuitive.

Weight Loss and Metabolic Improvements

Weight loss is one of the most consistent and dramatic effects of GLP-1 drugs in PCOS. In a study of obese women with PCOS who had not responded to lifestyle changes alone, three months of semaglutide treatment produced an average weight loss of about 7.6 kg, with some participants losing as much as 12 kg. Fasting glucose, insulin levels, and a standard measure of insulin resistance all dropped significantly, and 80% of participants who had elevated fasting glucose returned to normal levels.⁴

A meta-analysis pooling data from multiple trials found that semaglutide reduced BMI by roughly 2.2 kg/m² on average, with greater reductions at higher doses and in women whose starting BMI was above 28.⁵ These are meaningful numbers. Even a 5-10% reduction in body weight can shift hormone levels enough to restart ovulation in some women, and GLP-1 drugs routinely achieve that range in PCOS populations.

Effects on Testosterone and Other Hormones

The hormonal improvements go beyond what you would expect from weight loss alone, though weight loss is doing a lot of the heavy lifting. Across multiple studies using different GLP-1 drugs, including liraglutide and exenatide, researchers have consistently found decreases in free testosterone levels and increases in sex hormone-binding globulin, or SHBG, a protein that binds testosterone and makes it less biologically active.⁶ The net effect is lower androgen activity, which is what drives improvements in symptoms like acne and unwanted hair growth.

A narrative review of clinical studies found that liraglutide treatment also led to reduced ovarian volume and lower free testosterone, though it did not appear to change levels of LH, FSH, or anti-Müllerian hormone, and scores on the Ferriman-Gallwey scale, which measures excess body hair, did not improve significantly during the treatment period studied.⁷ That last point is worth noting: while androgen levels in the blood drop relatively quickly, visible changes in hair growth take much longer because of the hair growth cycle itself. A woman may see her testosterone normalize months before she notices any change in unwanted hair.

Menstrual Regularity and Natural Pregnancy Rates

For many women with PCOS, the most important question is whether treatment can restore regular periods and improve their chances of conceiving. The evidence here is encouraging. A systematic review and meta-analysis found that GLP-1 receptor agonist use was associated with an improvement in natural pregnancy rates, with treated women roughly 72% more likely to conceive naturally compared to those on metformin alone or placebo. Menstrual regularity also improved, and subgroup analysis showed that longer treatment durations, around 24 to 32 weeks, produced better outcomes for cycle regularity than shorter courses of 12 weeks.⁸

A systematic review of GLP-1 receptor agonists and reproductive health confirmed these patterns across studies, finding consistent improvements in menstrual regularity, reductions in body weight and central fat, higher SHBG levels, and lower free testosterone in overweight and obese women with PCOS.⁹ The picture that emerges is that GLP-1 drugs do not directly trigger ovulation. Instead, by normalizing insulin levels and reducing androgen excess, they create the metabolic conditions under which the ovaries can resume functioning more normally.

How GLP-1 Compares to Metformin

Metformin has been the go-to insulin-sensitizing drug for PCOS for decades, so the natural question is how GLP-1 drugs stack up against it. A systematic review and meta-analysis comparing the two found that GLP-1 receptor agonists were more effective than metformin at improving insulin sensitivity, reducing BMI, and shrinking waist circumference. The trade-off was a higher rate of nausea and headache with GLP-1 drugs, though other adverse events were comparable between the two.¹⁰

That said, the comparison is not entirely straightforward. Metformin is cheap, widely available, well-studied over decades, and has a safety profile that clinicians are deeply familiar with. GLP-1 drugs are expensive, often require injection, and their long-term effects in PCOS populations are less well characterized. For women whose primary issue is moderate insulin resistance without severe obesity, metformin may still be the reasonable first choice. The advantage of GLP-1 drugs becomes clearer in women with more significant obesity and insulin resistance who have not responded adequately to metformin and lifestyle changes.

Adding GLP-1 to Metformin

Rather than choosing one or the other, several research teams have tested what happens when you add a GLP-1 drug to ongoing metformin therapy. The results are consistently better than metformin alone. A comprehensive meta-analysis found that the combination produced greater reductions in body weight, BMI, waist circumference, fasting glucose, and insulin resistance compared to metformin by itself. Hormonal markers also improved more: SHBG levels rose significantly in the combination group. Importantly, the rate of adverse events was not significantly different between the combination and metformin-alone groups.¹¹

A prospective trial combining semaglutide with metformin found that after 16 weeks, the combination group lost an average of about 6 kg compared to just over 2 kg in the metformin-only group. The combination group also had higher rates of menstrual cycle recovery and, during a follow-up period extending to 40 weeks, a natural pregnancy rate of 35% compared to 15% in the metformin-only group.¹² A separate meta-analysis focused specifically on liraglutide plus metformin echoed these findings, showing superiority in BMI reduction, glucose control, lipid levels, menstrual regularity, ovulation rates, and spontaneous conception, though the combination group did experience more gastrointestinal side effects.¹³

Pregnancy Planning and When to Stop

Here is where things get serious for anyone thinking about fertility. GLP-1 drugs are not approved for use during pregnancy. Animal studies have raised concerns about fetal harm, and while limited human data on accidental early-pregnancy exposure have not shown a clear increase in congenital anomalies, the evidence is too thin to be reassuring.¹⁴

The washout period, the time you need to stop the drug before trying to conceive, varies by medication. Liraglutide has a short half-life and requires only a few days of washout. Semaglutide and tirzepatide, with their longer half-lives, need more lead time. Expert recommendations vary somewhat: one review suggests a general four-week washout for the agents studied, while another recommends eight to ten weeks for semaglutide and tirzepatide specifically.¹⁵ ¹⁶ The discrepancy reflects genuine uncertainty in the field, so it is worth discussing timing explicitly with your prescriber.

There is also a practical concern with tirzepatide and oral contraceptives. Because these drugs slow gastric emptying, they can reduce the absorption and effectiveness of birth control pills, which matters for any woman on the drug who is not trying to conceive.¹⁶ Non-oral contraceptive methods, such as an IUD or injection, sidestep this issue entirely.

Tirzepatide and Dual-Agonist Drugs

Tirzepatide is the most prominent of a newer class of drugs that activate both the GLP-1 receptor and the GIP receptor, another gut hormone involved in insulin secretion and metabolism. Because it hits two targets instead of one, tirzepatide has shown even more dramatic weight loss in general obesity trials than single-agonist GLP-1 drugs. Researchers have hypothesized that it may be particularly useful for PCOS given that the syndrome involves both insulin resistance and obesity.¹⁷

Early clinical data supports that hypothesis. A prospective randomized trial of tirzepatide combined with metformin versus metformin alone in overweight and obese Chinese women with PCOS found striking differences after 16 weeks. The combination group lost an average of about 10.4 kg, compared to just 1.7 kg in the metformin-only group. Visceral fat dropped dramatically, and the combination group saw greater improvements in reproductive and metabolic markers, with higher rates of menstrual cycle recovery and pregnancy.¹⁸ These are early results from a single trial, but the magnitude of difference is hard to ignore.

Benefits Beyond Reproductive Health

PCOS does not stop at the ovaries. Women with the syndrome carry higher risks for fatty liver disease, cardiovascular problems, and chronic inflammation. GLP-1 drugs appear to help with some of these associated conditions. A study of liraglutide in obese women with both PCOS and nonalcoholic fatty liver disease found that treatment reduced a marker of liver fibrosis significantly in the PCOS group, alongside improvements in weight, insulin resistance, inflammatory markers, and triglycerides.¹⁹

This matters because liver disease in PCOS often goes unrecognized. Many women are treated for their reproductive symptoms while their metabolic health quietly deteriorates. The fact that GLP-1 drugs address multiple organ systems simultaneously is one of their most appealing features for a syndrome that is, at its core, a multisystem metabolic disorder.

Mood, Anxiety, and Quality of Life

PCOS takes a significant psychological toll. Depression and anxiety rates are elevated in women with the syndrome, driven by a combination of hormonal disruption, body image distress, fertility concerns, and the daily burden of managing symptoms. A few studies have looked at whether GLP-1 treatment improves psychological well-being beyond just fixing metabolic numbers.

A six-month trial of liraglutide in young obese women with PCOS found that psychological health improved by about 11% on a standardized quality-of-life questionnaire, with gains in physical, psychological, and social well-being domains. The researchers concluded that weight loss itself was the main driver of these improvements, and that when matched for age and obesity, PCOS was not independently associated with worse quality of life or depression.²⁰ A separate randomized trial of semaglutide showed improvements in well-being scores and reductions in anxiety and depression measures within the treatment group, though the differences did not reach statistical significance when compared directly to the control group.²¹ The psychological benefits are real but appear to be largely mediated by weight loss and improved metabolic health rather than a direct mood-enhancing effect of the drug.

Side Effects and Tolerability

The most common side effects of GLP-1 drugs are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are particularly common during the first few weeks as the dose is being titrated upward. Most clinicians start at a low dose and increase gradually to minimize these effects, and for the majority of users the symptoms ease over time. In head-to-head comparisons with metformin, GLP-1 drugs tend to produce more nausea and headache, though metformin has its own well-known gastrointestinal side effects.¹⁰

When GLP-1 drugs are added to metformin rather than replacing it, the tolerability picture is mixed. One meta-analysis of the combination found no significant difference in adverse events between the combo group and metformin alone, while another specifically noted more gastrointestinal reactions with the combination.¹³ In practice, individual tolerance varies widely. Some people sail through dose escalation; others need to slow down or switch medications.

What About Teenagers With PCOS

PCOS often shows up during adolescence, and the question of whether GLP-1 drugs are appropriate for younger patients is getting more attention as these medications become widely prescribed for weight management. The short answer is that there is almost no direct evidence. A systematic review of non-hormonal treatments for adolescent PCOS found no published trials of GLP-1 receptor agonist monotherapy in this population.²²

General adolescent obesity trials of liraglutide and semaglutide have shown significant weight reduction without short-term effects on growth or puberty. But adolescence is when peak bone mass is being built, and rapid pharmacologic weight loss could theoretically interfere with bone mineral accrual. Adult data suggest modest reductions in bone density associated with weight loss on these drugs, which may be offset by exercise. There are also legitimate concerns about the potent appetite-suppressing effects of these drugs in a population already vulnerable to disordered eating and body image pressures.²³ For now, prescribing GLP-1 drugs to adolescents with PCOS remains an off-label, case-by-case decision that requires careful weighing of risks and benefits.

The Question of What Happens When You Stop

One issue that gets less airtime than it deserves is weight regain after discontinuing GLP-1 drugs. In general obesity populations, studies have shown that a substantial portion of lost weight returns within a year of stopping treatment. For PCOS, the concern is that the metabolic and hormonal improvements may also reverse if the underlying insulin resistance returns alongside regained weight. No large, long-term discontinuation studies specific to PCOS have been published, but the biology suggests that the benefits are at least partly dependent on continued treatment or on successfully maintaining weight loss through other means after stopping.

This does not mean treatment is pointless if it is not lifelong. A period of GLP-1-assisted weight loss and metabolic improvement may create a window for conception, or for establishing exercise and dietary habits that help sustain some of the gains. Some clinicians use GLP-1 drugs as a bridge: achieve metabolic improvement, restore ovulation, pursue pregnancy, then stop the medication during the required washout period. Whether the benefits persist long enough for that strategy to work consistently is an active area of research.

Access, Cost, and Off-Label Use

As of now, no GLP-1 receptor agonist carries an FDA-approved indication specifically for PCOS. When these drugs are prescribed for PCOS, it is technically off-label, even though the evidence base is growing. Some women qualify for a GLP-1 prescription through an obesity or type 2 diabetes diagnosis, both of which frequently coexist with PCOS, but others fall into a coverage gap where their BMI or blood sugar does not quite meet the threshold for insurance approval even though their PCOS would benefit from treatment.

The cost barrier is real. Without insurance coverage, GLP-1 drugs can run well over a thousand dollars per month, and generic versions are not yet widely available for the newer agents like semaglutide and tirzepatide. Compounding pharmacies have filled some of the gap, though the quality and dosing consistency of compounded formulations are areas of ongoing regulatory scrutiny. For women considering this treatment, a candid conversation with their prescriber about insurance pre-authorization strategies, manufacturer savings programs, and which specific agent is most likely to be covered can make the difference between starting treatment and being priced out.

1
Europe PMC. Insulin and hyperandrogenism in women with polycystic ovary syndrome
2
PubMed Central. Glucagon-like peptide 1 (GLP-1)
3
PubMed Central. An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
4
PubMed Central. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
5
PubMed. Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients
6
Advances in Clinical and Experimental Medicine. GLP-1 receptor agonists, polycystic ovary syndrome, and reproductive dysfunction: Current research and future horizons
7
Endocrine Connections. Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
8
PubMed Central. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review
9
PubMed Central. A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms
10
PubMed. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
11
PubMed. Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis
12
PubMed Central. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome
13
PubMed Central. The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis
14
PubMed Central. GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review
15
PubMed Central. Glucagon-like peptide-1 receptor agonists and safety in the preconception period
16
PubMed Central. GLP-1 Receptor Agonists and Fertility: What Is Known So Far?
17
PubMed Central. The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
18
PubMed Central. Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome
19
PubMed. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
20
PubMed. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls
21
Metabolism and Target Organ Damage. Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial
22
Journal of Pediatric and Adolescent Gynecology. Nonhormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review
23
PubMed. GLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns